Latest Cambridge Heart Inc (CAMH) Headlines C
Post# of 6
Posted On: 03/09/2014 5:34:41 AM
Latest Cambridge Heart Inc (CAMH) Headlines
Cardiovascular Disease Diagnostics: In Vitro Diagnostics, and In Vivo Diagnostics - Global Strategic Business Report
M2 - Tue Feb 12, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/55ndtk/cardiovascular) has announced the addition of the "Cardiovascular Disease Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following Two Broad Segments: In Vitro Diagnostics, and In Vivo Diagnostics. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 70 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Cholestech Corp., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biom?rieux, Cambridge Heart, Inc., GE HealthCare, Home Access Health Corporation, LifeSign LLC, Liposcience, Inc., Nanosphere, Inc.,
Cambridge Heart Provides Update
Marketwire - Tue Jan 08, 4:00PM CST
Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, announced today that preliminary revenue for the quarter and year ended December 31, 2012 was approximately $305,600, and $1,740,300, respectively. Cash and cash equivalents were an estimated $38,000.
Cardiovascular Disease Diagnostics: In Vitro Diagnostics, and In Vivo Diagnostics - Global Strategic Business Report
M2 - Tue Feb 12, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/55ndtk/cardiovascular) has announced the addition of the "Cardiovascular Disease Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following Two Broad Segments: In Vitro Diagnostics, and In Vivo Diagnostics. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 70 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Cholestech Corp., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biom?rieux, Cambridge Heart, Inc., GE HealthCare, Home Access Health Corporation, LifeSign LLC, Liposcience, Inc., Nanosphere, Inc.,
Cambridge Heart Provides Update
Marketwire - Tue Jan 08, 4:00PM CST
Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, announced today that preliminary revenue for the quarter and year ended December 31, 2012 was approximately $305,600, and $1,740,300, respectively. Cash and cash equivalents were an estimated $38,000.
(0)
(0)Cambridge Heart, Inc. (CAMH) Stock Research Links
Scroll down for more posts ▼